Gilead Palo Alto (formerly CV Therapeutics) is honed in on cardiovascular research. The drug development company specializes in pharmaceuticals to treat chronic cardiovascular diseases. The firm's drug Ranexa, licensed from a Roche subsidiary, is FDA-approved as a first-line and second-line treatment for patients with chronic angina (chest pain). Gilead Palo Alto won approval for its cardiac imaging agent, Lexiscan, in 2008; the drug is marketed by Astellas Pharma. The company is developing potential therapies for ailments including heart failure and atrial fibrillation (irregular heartbeat). Gilead Palo Alto changed its name from CV Therapeutics after being acquired by Gilead Sciences in 2009.

Morphotek has mighty morphin' power, but don't expect to find its products on the shelves of the local toy store. The biotechnology company develops monoclonal antibody (single-source protein) therapies for the treatment of cancer, inflammation, and infectious diseases using its proprietary Morphogenics technology platform. It conducts research and clinical development programs on its own drug candidates for ailments such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. Morphotek also enters collaborative research partnerships and licenses out its technology to other drug companies such as Amgen and Novo Nordisk. The company is a subsidiary of Eisai Inc., part of Japanese drug firm Eisai.

Peplin, Inc. company is developing drugs aimed at treating potentially cancerous skin conditions. Its lead drug candidate, a topical gel, is intended to serve as a less-costly alternative to surgical treatments for a common pre-cancerous skin condition known as actinic keratosis (AK). Derived from a plant known as petty spurge or radium weed, the product will be used to treat AK (characterized by rough patches of skin resulting from excessive exposure to sunlight) before it develops into skin cancer. Peplin was acquired by pharmaceutical giant LEO Pharma in late 2009 for $285 million.

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Established in 1968 by French vet Pierre-Richard Dick, Virbac provides biological and pharmaceutical products for veterinary and animal health use and is one of the 10 biggest veterinary pharmaceutical companies in the world. Products include vaccines, flea treatments, wormers, and antibiotics for animals. With some 20 subsidiaries (including US-based Virbac Corporation), the company's products are sold in more than 100 countries. Virbac's companion animal segment (dogs, cats, horses) represents more than 60% of the company's sales, while its food-producing animal segment (cows, chickens, cattle) brings in about 37%. The founding Dick family owns about 50% of the company.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

Urigen Pharmaceuticals, Inc. (Urigen) is a specialty pharmaceutical company engaged in the development and commercialization of therapeutic products for urological disorders. The Company’s product pipeline includes URG101, for the treatment of Painful Bladder Syndrome (PBS), which has completed a Phase II double blinded, placebo controlled, multi-center trial, and URG301, targeting urethritis and nocturia. Urigen specializes in the development of products for patients with urological ailments including, specifically, the development of products for amelioration Painful Bladder Syndrome/Interstitial Cystitis (PBS or PBS/IC), Urethritis, Nocturia and Overactive Bladder (OAB). Urology represents a specialty pharmaceutical market of approximately 12,000 physicians in North America. Urologists treat a variety of ailments of the urinary tract including urinary tract infections, bladder cancer, overactive bladder, urgency and incontinence and interstitial cystitis, a subset of PBS.

Rigel Pharmaceuticals, Inc. company was founded in 1996 and is based in South San Francisco, California. Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Its product development portfolio includes R788, which is in Phase 2b clinical trial for the treatment of rheumatoid arthritis (RA); a Phase 2 clinical trial for the treatment of immune thrombocytopenia purpura, B-cell lymphoma, and T-cell lymphoma; and a preclinical stage for the treatment of lupus. Rigel company's products also include R348, which is in Phase 1 clinical trial for Psoriasis; R763, which is in Phase 1 clinical trial in the area of oncology; and R343, a Phase 1 clinical trial product for asthma. It has collaboration agreements with Janssen Pharmaceutica N.V.; Pfizer, Inc.; Novartis Pharma AG; Daiichi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; and Merck Serono.

Omnicare Clinical Research is a contract research organization (CRO) offering drug development services, from Phase I to Phase IV clinical trials, to drug and medical device companies worldwide. A unit of nursing home pharmacy operator Omnicare, the CRO has special expertise in the area of geriatrics research and takes advantage of its parent's access to geriatric patient populations and investigators. However, the unit also provides support in numerous other therapeutic areas, including cardiovascular, dermatology, metabolism, and infectious disease. Services include patient and investigator recruitment, drug packaging and distribution, clinical trials management, and medical writing.

BioFocus DPI takes the guesswork out of your drug discovery. The UK-based company specializes in pre-clinical drug discovery services, assay development and screening, and compound management (including storage and delivery). The company's major clients include Pfizer, Procter & Gamble, and GlaxoSmithKline. BioFocus was founded by a group of Wellcome scientists in 1997, and about a decade later was acquired by Galapagos. It now operates as that company's services division. Formerly known as BioFocus, the firm added DPI to its name after Galapagos acquired the drug discovery business of Discovery Partners International and merged it with existing BioFocus operations.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.